Please assess the completion status of the following clinical trial:

Trial Title: Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eGFR \&lt; 30 mL/min~* Hb 90-110 g/L~* Age \&gt; 18~* Not on renal replacement therapy~* Transferrin saturation \&lt; 20% OR Ferritin \&lt;100 mcg/L~* B12 \& folate within reference range~Exclusion Criteria:~1. Iron overload (Tsat \> 50% or ferritin \> 800 μg/L);~2. malignancy; recurrent gastro-intestinal bleeding, major surgery or infection within the last 3 months;~3. parenteral iron therapy, blood transfusion within the last 3 months;~4. pregnancy;~5. contraindication to any study medication and;~6. inability or refusal to give consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heme Iron (Type: EXPERIMENTAL): Heme Iron Polypeptide 11mg PO tid for 6 months
- Venofer (Type: ACTIVE_COMPARATOR): Venofer q month IV x 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).